Seoulin Bioscience Co.Ltd (038070) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Seoulin Bioscience Co.Ltd stock KRW 4,246, price KRW 3,365, upside +26.2%, quality 51 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 3,365 KRW – 34,201 KRW · fair‑value band 2,803 KRW – 5,308 KRW · the 3,365 KRW price screens below the 4,246 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 3, 2026.
Follow Seoulin Bioscience Co.Ltd in your weekly email
Every Wednesday you see whether Seoulin Bioscience Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea.
Show moreShow less
The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and functional cosmetics based on natural fermentation.
Seoulin Bioscience Co.,Ltd. was founded in 1984 and is headquartered in Seongnam-si, South Korea.
Stock analysis
Seoulin Bioscience Co.Ltd (038070) currently trades at 3,365 KRW, while our model-based Fair Value estimate is 4,246 KRW, implying the stock looks roughly 21% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 7,110 KRW per share, and 13 of the 26 models we run sit above the 3,365 KRW price.
Bear case: the Earnings-Based group reads lowest at 1,063 KRW, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 2,803 KRW (bear) to 5,308 KRW (bull), the price of 3,365 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Seoulin Bioscience Co.Ltd reported revenue of 77.1B KRW in FY2025 versus 80.5B KRW in FY2021, a compound −1.1%/yr. Reported net income was 732M KRW in FY2025, compounding −53.5%/yr from FY2021.
Key figures
Market cap 29.7B KRW (≈ $22.0M) Micro · P/E ratio 32.9 · P/S ratio 0.36 · EPS (TTM) 103.94 KRW · Dividend yield 3.0% · Net margin 1.1% · Return on equity 1.0% · Return on assets (EBIT) 2.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).
What moves the price
The share trades about 50% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 26%, 038070 screens cheaper than that median.
Fair Value models
Bear2,803 KRWFair Value 4,246 KRWBull5,308 KRW
Price 3,365 KRW · Upside +26.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.38 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Start year 2020 (pandemic). Over 10 years: +6.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−37.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−40.2%
Dividend (yield on the price)3.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−40.2% vs −16.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 1%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−19.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −20.6% a year for the price.
Compare Seoulin Bioscience Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside+26.2% · Top 25%
Profitability
Return on equity (12 months)1.0% · Above median
Return on assets0.6% · Above median
Net margin (12 months)1.1% · Below median
Operating margin (12 months)−2.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)28.2% · Top 25%
Dividend yield (12 months)3.0% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Seoulin Bioscience Co.Ltd (038070) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 4,246 KRW versus a price of 3,365 KRW, about +26% upside (undervalued).
What is the fair value of 038070?
Our model-based fair value for Seoulin Bioscience Co.Ltd is 4,246 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 3,365 KRW.
What is the quality score of 038070?
Seoulin Bioscience Co.Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seoulin Bioscience Co.Ltd (038070)?
Our model-based price target is the fair value of 4,246 KRW (as of Nov 3, 2026) from 26 valuation models. Cautious scenario 2,803 KRW, optimistic scenario 5,308 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Seoulin Bioscience Co.Ltd stock forecast for 2026?
Our models put fair value at 4,246 KRW, about +26% upside versus a price of 3,365 KRW (undervalued). Cautious scenario 2,803 KRW, optimistic scenario 5,308 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Seoulin Bioscience Co.Ltd (038070)?
Seoulin Bioscience Co.Ltd reported trailing-twelve-month revenue of about 83.2B KRW (latest available figure, as of Nov 3, 2026).
Does Seoulin Bioscience Co.Ltd pay a dividend?
Seoulin Bioscience Co.Ltd currently shows a dividend yield of 2.97% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Seoulin Bioscience Co.Ltd (038070) and when is the ex-dividend date?
Seoulin Bioscience Co.Ltd pays a dividend of 100.00 KRW per share a year, a dividend yield of 3.0%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2005. The payout ratio is 96.2% of earnings. Free cash flow covers the dividend 4.82 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Seoulin Bioscience Co.Ltd (038070)?
For today's price to be fair in a discounted-cash-flow model, Seoulin Bioscience Co.Ltd would have to grow free cash flow by -19.0 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 038070 use?
Our models discount Seoulin Bioscience Co.Ltd at 9.1 %: a base by market capitalisation (nano), damped by beta 0.57, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seoulin Bioscience Co.Ltd that is -19.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Seoulin Bioscience Co.Ltd (038070) delivered so far?
Over the past 5 years revenue at Seoulin Bioscience Co.Ltd grew +3.4 % a year. The price currently implies free-cash-flow growth of -19.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seoulin Bioscience Co.Ltd (038070) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Seoulin Bioscience Co.Ltd (-19.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seoulin Bioscience Co.Ltd (038070)?
The free-cash-flow yield on the price is 14.32 %: that much free cash flow Seoulin Bioscience Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seoulin Bioscience Co.Ltd (038070)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seoulin Bioscience Co.Ltd it is 4,246 KRW per share (as of Nov 3, 2026), against a price of 3,365 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Seoulin Bioscience Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 038070 trades below its calculated fair value: price 3,365 KRW, fair value 4,246 KRW, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 038070?
No. The price is what the market pays today (3,365 KRW); the fair value is what the company's own numbers justify (4,246 KRW). For Seoulin Bioscience Co.Ltd the two are 881.42 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Seoulin Bioscience Co.Ltd worth?
The market values Seoulin Bioscience Co.Ltd at about 29.7B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 3,365 KRW; our models calculate a fair value of 4,246 KRW per share.
What do the bullish and bearish scenarios say about 038070?
Our models span a range for Seoulin Bioscience Co.Ltd: cautious scenario 2,803 KRW, base 4,246 KRW, optimistic 5,308 KRW per share (as of Nov 3, 2026, price 3,365 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 038070?
Seoulin Bioscience Co.Ltd trades at a price-to-earnings ratio of 32.9 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4,246 KRW is built from several models across several years. Other multiples: P/B 0.4, P/S 0.4, EV/EBITDA 11.4.
How solid is the balance sheet of Seoulin Bioscience Co.Ltd (038070)?
Balance-sheet figures for Seoulin Bioscience Co.Ltd (as of Nov 3, 2026): return on equity 1.0%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 038070 from its 52-week high?
Seoulin Bioscience Co.Ltd trades at 3,365 KRW, about 50% below its 52-week high of 6,760 KRW and at the low of 3,365 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4,246 KRW is for.
Which stocks are comparable to Seoulin Bioscience Co.Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seoulin Bioscience Co.Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 3,365 KRW, calculated fair value 4,246 KRW (+26%), Quality Score 51/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 038070 calculated?
We run Seoulin Bioscience Co.Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4,246 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Seoulin Bioscience Co.Ltd currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Seoulin Bioscience Co.Ltd (038070)?
The closing price on Nov 6, 2026 was 3,365 KRW. Our model-based fair value is 4,246 KRW, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seoulin Bioscience Co.Ltd right now?
Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (2,803 KRW to 5,308 KRW) leaves room in how you read the outcome.
Key figures of Seoulin Bioscience Co.Ltd
How large is the market capitalisation of Seoulin Bioscience Co.Ltd (038070)?
The market capitalisation of Seoulin Bioscience Co.Ltd is 29.7B KRW (≈ $22.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seoulin Bioscience Co.Ltd (038070)?
The price-to-sales ratio of Seoulin Bioscience Co.Ltd is 0.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seoulin Bioscience Co.Ltd (038070)?
Earnings per share at Seoulin Bioscience Co.Ltd are 103.94 KRW (price ÷ EPS = P/E 32.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Seoulin Bioscience Co.Ltd (038070)?
The dividend yield of Seoulin Bioscience Co.Ltd is 3.0% (payout 96.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Seoulin Bioscience Co.Ltd (038070)?
The net margin of Seoulin Bioscience Co.Ltd is 1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Seoulin Bioscience Co.Ltd (038070)?
The return on equity (ROE) of Seoulin Bioscience Co.Ltd is 1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seoulin Bioscience Co.Ltd (038070)?
On an EBIT basis the return on assets of Seoulin Bioscience Co.Ltd is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seoulin Bioscience Co.Ltd (038070)?
The operating margin of Seoulin Bioscience Co.Ltd is −2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seoulin Bioscience Co.Ltd (038070)?
Revenue at Seoulin Bioscience Co.Ltd is growing +28.2% versus a year earlier (3y avg −9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seoulin Bioscience Co.Ltd (038070)?
Earnings per share at Seoulin Bioscience Co.Ltd are growing −57.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Seoulin Bioscience Co.Ltd (038070) carry?
The net debt of Seoulin Bioscience Co.Ltd is 969M KRW (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Seoulin Bioscience Co.Ltd in the live analysis
One click puts Seoulin Bioscience Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026